ERBB2 and breast cancer: Most relevant to BC treatment, dual treatment of ErbB2-positive BC with both the anti-ErbB2 antibody trastuzumab and the tyrosine kinase inhibitor lapatinib resulted in a much higher response rate when compared to administration of either therapy alone [6].